Researchers at the University of Michigan Medical School and the University at Buffalo have developed a new cancer treatment that could dramatically cut the rates of new cases.
The research, published in the journal Nature Medicine, found that the new drug, called ocrelizumab, has an extremely high rate of survival and that it works better than a standard drug.
It was the first study to show that a cancer treatment could be effective and safe in a large trial, said lead study author Dr. Richard M. Schoenfeld, a professor of clinical medicine at the U-M School of Medicine.
The ocrescriptumab is a protein that targets the genes that are responsible for cancer formation.”
Our results suggest that a very small proportion of patients can benefit from a small percentage of the available chemotherapy and radiation, so we think that the drug can be effective.”
The ocrescriptumab is a protein that targets the genes that are responsible for cancer formation.
Ocrelosumab also inhibits the production of tumor-causing proteins called p53 and calpain proteins.
In addition, it reduces the risk of developing cancers and other autoimmune disorders.
In the current trial, patients receiving ocreosumabs took two doses a week for two months.
Those receiving standard chemotherapy and standard radiation had to take another dose.
Patients receiving ocsurab also took another dose of standard chemotherapy twice a week, but only once a week.
The drug’s effectiveness was determined in a controlled, randomized, double-blind, placebo-controlled study.
Patients were randomly assigned to receive ocregizumabs, a standard chemotherapy regimen or standard radiation.
Both chemotherapies were given at the same time.
Patients took their baseline readings on a regular basis.
The results were recorded.
The patients who received ocrosumab were given one of two different doses, and those who received standard chemotherapy received one of four different doses of the drug, which was identical to the treatment given to those who did not receive the drug.
The four different dosages included ocrolosumabi, which had a higher incidence of serious side effects, and ocrole, which has a higher rate of side effects.
The results showed that ocruzumab resulted in an 18 percent reduction in the incidence of tumors in those who were given ocrorumab and a 34 percent reduction of the incidence in those not receiving otcregizab.
Ours was a good study, Dr. Schönfeld said.
“This was an interesting study, and it’s a promising example of what can be done with new cancer drugs.”
In the next phase of the trial, more patients will be randomly assigned, and the results will be compared with those who have received standard chemo or radiation.
The study was funded by the National Institutes of Health (grant R01MH082955), the Robert Wood Johnson Foundation (grants R01HF107541, R01HC083944, R03MH083789, R21MH102225 and R21HC091030) and the National Cancer Institute.